Are GlaxoSmithKline plc & National Grid plc The Only Shares You Need To Own?

Roland Head asks whether National Grid plc (LON:NG) and GlaxoSmithKline plc (LON:GSK) have market-beating potential.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Is it possible to run a successful portfolio with just two shares? I wouldn’t recommend it, but if I decided to try, National Grid (LSE: NG) and GlaxoSmithKline (LSE: GSK) would probably be on my shortlist of stocks to consider.

Both companies appear to offer a combination of reliable long-term growth and generous dividend yields. Both firms are also very large. Together, National Grid and Glaxo account for 5.7% of the FTSE 100’s total market capitalisation. This makes them less likely than smaller companies to fail, although long periods of underperformance are still possible.

Not likely to underperform?

Indeed, many investors believe that GlaxoSmithKline has been underperforming over the last few years. Although the dividend has been maintained, the firm’s shares are currently trading 15% below their July 2013 high of 1,745p.

However, things now seem likely to change. Glaxo completed a major asset swap deal with Swiss firm Novartis last year. The firm’s sales rose by 4% and while profits were lower, a number of new products made a strong contribution for the first time.

I believe Glaxo’s restructuring has positioned it to deliver a sustained period of growth. Adjusted earnings per share are expected to rise to 85.3p this year, covering the firm’s forecast dividend of 81.9p per share for the first time in three years.

There’s also one more big change in the pipeline. The group’s chief executive, Sir Andrew Witty, is expected to leave next year. If GlaxoSmithKline shares continue to underperform the market, I suspect its next chief executive will come under pressured to break up the group.

Fund managers such as Neil Woodford hold the view that Glaxo would be worth more as two or three companies than it is as one. I suspect he’s right, although I like the defensive nature of Glaxo’s diverse portfolio.

In the meantime, I believe GlaxoSmithKline’s 5.5% dividend yield and long-term growth potential make the shares a strong buy.

Heading in the opposite direction?

While GlaxoSmithKline may have underperformed the market, National Grid hasn’t.

Over the last five years, shares in National Grid have risen by 69%, compared to just 3% for the FTSE 100. The two other large listed power utilities in the UK, SSE and Centrica, have also lagged National Grid. Centrica has fallen by nearly 30% over the same period, while SSE has gained just 17%.

National Grid also has a couple of other attractive features. The firm’s US utility business helps diversify the group’s operations and reduce its dependency on the UK market. Another attraction is that unlike electricity generators like SSE and Centrica, National Grid’s direct exposure to coal, oil and gas prices is very low.

I can’t see any reason why National Grid’s business can’t continue to perform strongly. My only reservation is that the shares are no longer obviously cheap. Dividend growth has now slowed to just 1% to 2% a year. And National Grid’s 4.3% yield is well below the 6% on offer from SSE.

However, analysts have a positive outlook for the next couple of years. Forecast earnings for 2015/16 have risen by 5.5% over the last year. There’s a real possibility that National Grid will continue to outperform its utility peers.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Roland Head owns shares of GlaxoSmithKline and SSE. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Passive income text with pin graph chart on business table
Investing Articles

Does a 9.3% yield and a growing dividend make Legal & General shares a passive income no-brainer?

Legal & General shares have been a bad investment over the last five years. But could it be a huge…

Read more »

Charticle

2 brilliant (but very different) shares I want to buy if they get cheaper in 2025!

This contrasting pair of businesses has caught our writer's eye. But he is not ready to buy the shares at…

Read more »

Investing Articles

3 steps to start buying shares with a spare £250

Christopher Ruane explains three simple but important principles he thinks people should consider when they start buying shares, even with…

Read more »

Light trails from traffic moving down The Mound in central Edinburgh, Scotland during December
Investing Articles

FTSE 100 shares: bargain hunting to get richer!

After hitting a new high this year, might the FSTE 100 still offer bargain shares to buy? Our writer thinks…

Read more »

Investing Articles

How to try and turn a £50K SIPP into a £250K retirement fund

Christopher Ruane explains how a long-term approach and careful share selection could potentially help an investor quintuple the value of…

Read more »

Smiling white woman holding iPhone with Airpods in ear
Investing Articles

My £3 a day passive income plan for 2025

Christopher Ruane walks through his plan for next year and beyond of squirreling away and investing a few pounds a…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Can the FTSE 250’s Raspberry Pi boost my portfolio over the next decade?

This British technology stock in the FTSE 250 has exploded onto the London stock market and right now its future…

Read more »

Investing Articles

Does acquiring Direct Line make Aviva shares a buy?

A big acquisition should give Aviva greater scale and profitability, increasing the value of its shares. But is it an…

Read more »